The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index.
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Open accessAbstract
BACKGROUND: Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in phase 2 studies. We conducted a phase 3 trial to evaluate the safety and efficacy of 52 weeks of treatment with evolocumab. METHODS: We stratified patients with hyperlipidemia according to the risk categories outlined by the Adult Treatment Panel III of the National Cholesterol Education Program. On the basis of this classification, patients were started on background lipid-lowering therapy with diet alone or diet plus atorvastatin at a dose of 10 mg daily, atorvastatin at a dose of 80 mg daily, or atorvastatin at a dose of 80 mg daily plus ezetimibe at a dose of 10 mg daily, for a run-in period of 4 to 12 weeks. Patients with an LDL cholesterol level of 75 mg per deciliter (1.9 mmol per liter) or higher were then randomly assigned in a 2:1 ratio to receive either evolocumab (420 mg) or placebo every 4 weeks. The primary end point was the percent change from baseline in LDL cholesterol, as measured by means of ultracentrifugation, at week 52. RESULTS: Among the 901 patients included in the primary analysis, the overall least-squares mean (±SE) reduction in LDL cholesterol from baseline in the evolocumab group, taking into account the change in the placebo group, was 57.0±2.1% (P<0.001). The mean reduction was 55.7±4.2% among patients who underwent background therapy with diet alone, 61.6±2.6% among those who received 10 mg of atorvastatin, 56.8±5.3% among those who received 80 mg of atorvastatin, and 48.5±5.2% among those who received a combination of 80 mg of atorvastatin and 10 mg of ezetimibe (P<0.001 for all comparisons). Evolocumab treatment also significantly reduced levels of apolipoprotein B, non-high-density lipoprotein cholesterol, lipoprotein(a), and triglycerides. The most common adverse events were nasopharyngitis, upper respiratory tract infection, influenza, and back pain. CONCLUSIONS: At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in patients with a range of cardiovascular risks. (Funded by Amgen; DESCARTES ClinicalTrials.gov number, NCT01516879.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment of hyperlipidemic patients with monoclonal antibodies that target and inactivate PCSK9 results in increased hepatic LDLR expression and significantly reduced plasma LDL-C40,41.”
From RNF130 Regulates LDLR Availability and Plasma LDL Cholesterol Levels (2023) · cites this paper as [41]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment with PCSK9 inhibitors reduces LDL-C by approximately − 60% [75–79].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [79]
The cited source says what the claim attributes to it.
In the citing paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“ASO silencing of Rnf130 resulted in a 50% decrease in LDL-C, a change comparable to inhibiting PCSK940,41, further supporting that RNF130 is a significant regulator of LDLR and LDL-C levels.”
From RNF130 Regulates LDLR Availability and Plasma LDL Cholesterol Levels (2023) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., & Pordy, R. C. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60771-5 · Cited by 579
Self-citationMcKenney, J. M., Koren, M. J., Kereiakes, D. J., Hanotin, C., Ferrand, A.-C., & Stein, E. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.007 · Cited by 514
Self-citationRaal, F. J., Scott, R. C., Somaratne, R. M., Bridges, I. M., Li, G., Wasserman, S. M., & Stein, E. A. (2012) · Circulation · doi:10.1161/circulationaha.112.144055 · Cited by 506
Self-citationAtorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Roth, E. M., McKenney, J. M., Hanotin, C., Asset, G., & Stein, E. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201832 · Cited by 462
Self-citationLambert (2012) · doi:10.1194/jlr.r026658 · Cited by 448
Sullivan, D., Olsson, A. G., Scott, R., Kim, J. B., Xue, A., Gebski, V., Wasserman, S. M., & Stein, E. A. (2012) · JAMA · doi:10.1001/jama.2012.25790 · Cited by 447
Self-citationGiugliano, R. P., Desai, N. R., Kohli, P., Rogers, W. J., Somaratne, R. M., Huang, F., Liu, T., Mohanavelu, S., Hoffman, E. B., McDonald, S. T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61770-x · Cited by 428
Self-citation
Flagged first, then by citations
1 of the 16 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 722
Assaying Low-Density-Lipoprotein (LDL) Uptake into Cells
Loregger, A., Nelson, J. K., & Zelcer, N. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6875-6_5 · Cited by 12
Gebauer, K., & Reinecke, H. (2018) · VASA · doi:10.1024/0301-1526/a000689 · Cited by 11
Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab
Desai, N. R., Wade, R. L., Xiang, P., Pinto, L. A., Nunna, S., Wang, X., Exter, J., Mues, K. E., Habib, M., & Chen, C. (2021) · Clinical Cardiology · doi:10.1002/clc.23600 · Cited by 12
Diabetes in Population Isolates: Lessons from Greenland
Grarup, N., Moltke, I., Albrechtsen, A., & Hansen, T. F. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.320 · Cited by 12
FH through the retrospectoscope
Thompson, G. R. (2020) · Journal of Lipid Research · doi:10.1194/jlr.tr120001001 · Cited by 11
LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?
Hewing, B., & Landmesser, U. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0610-z · Cited by 11
PCSK9 in Vascular Aging and Age-Related Diseases
Tan, D., Yang, X., Yang, J., Fan, G., & Xiong, G. (2025) · Aging and Disease · doi:10.14336/ad.2024.1713 · Cited by 10
Jha, M., Agrawal, S. P., Maheta, D., Bhattacharjee, P., Jain, H., Zacks, J. S., Frishman, W. H., & Aronow, W. S. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2511063 · Cited by 10
PCSK9 Inhibitors and Their Role in high-risk Patients in Reducing Ldl Cholesterol Levels: Alirocumab
Dahagam, C., Goud, A., Abdelqader, A., Hendrani, A. D., Feinstein, M. J., Qamar, A., Joshi, P. H., Swiger, K. J., Byrne, K., Quispe, R., et al. (2016) · Future Cardiology · doi:10.2217/fca.15.88 · Cited by 10
Stein, E. A. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000242 · Cited by 10
Self-citationRetargeting the management of hypercholesterolemia – focus on evolocumab
Cicero, A. F. G., Colletti, A., & Derosa, G. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s116679 · Cited by 10
Association of PCSK9 Loss-of-Function Variants With Risk of Heart Failure
Trudsø, L. C., Ghouse, J., Ahlberg, G., Bundgaard, H., & OLESEN, M. S. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4798 · Cited by 10
Jacobsen, A. P., Whelton, S. P., Blumenthal, R. S., & McEvoy, J. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00042-6 · Cited by 13
Tailoring Treatment in Cardiovascular Diseases: The Role of Targeted Therapies
Dankar, R., Wehbi, J., & Refaat, M. M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040461 · Cited by 11
Iannuzzo, G., Kamboj, G., Barman, P., Dongare, S., & Jawla, S. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.10.001 · Cited by 10
Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia
Whayne, T. F. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0150-3 · Cited by 11
Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals
Wasserman, S. M., Sabatine, M. S., Koren, M. J., Giugliano, R. P., Legg, J. C., Emery, M. G., Doshi, S., Liu, T., Somaratne, R. M., & Gibbs, J. P. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418774043 · Cited by 10
Self-citationLeskelä, R., Torvinen, A., Rissanen, T. T., Virtanen, V., Herse, F., Nuutinen, M., Mustonen, J. N., & Laatikainen, T. K. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.01.018 · Cited by 13
Biotechnology Approaches for the Treatment of Dyslipidemia
Parolini, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07017-6 · Cited by 10
The effect of temperature on the stability of PCSK-9 monoclonal antibody: an experimental study
Kongmalai, T., Chuanchaiyakul, N., Sripatumtong, C., Tansit, T., Srinoulprasert, Y., Klinsukon, N., & Thongtang, N. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01447-3 · Cited by 10
Bellino, M., Galasso, G., Silverio, A., Tedeschi, M., Formisano, C., Romei, S., Esposito, L., Cancro, F. P., Vassallo, M. G., Accarino, G., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082922 · Cited by 10
Treatment of dyslipidemia: The problem of reaching the goal
Bolli, P. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.003 · Cited by 10
Recent developments in modulating atherogenic lipoproteins
White, C. R., Goldberg, D., & Anantharamaiah, G. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000216 · Cited by 10
Androulakis, E. S., Zacharia, E. M., Παπαγεωργίου, Ν., Lioudaki, E., Bertsias, D., Charakida, M., Siasos, G., & Tousoulis, D. (2017) · Current Cardiology Reviews · doi:10.2174/1573403x13666170209145622 · Cited by 10
The efficacy of anti-PCSK9 antibodies: Results from recent trials
Gouni‐Berthold, I. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.030 · Cited by 10
Imaging and Targeting Coronary Artery Inflammation
West, H. W., & Antoniades, C. A. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8128 · Cited by 10
Burnett, H. F., Cichewicz, A. B., Natani, H., Bhowmik, D., Buesch, K., Fahrbach, K. R., Reichelt, A., Neupane, B., Pierre, V. J., & Jindal, R. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001712 · Cited by 10
Parikh, R. R., Breve, F., Magnusson, P., Behzadi, P., & Pergolizzi, J. V. (2022) · Cureus · doi:10.7759/cureus.25641 · Cited by 10
Kayani, T., Ahmad, B., Chang, R., Qian, F., Sahinoz, M., Rehan, M., Giaimo, A., Spatz, E. S., & Hu, J. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3010009 · Cited by 9
The year in cardiology 2014: prevention
Backer, G. D., Kastelein, J. J. P., & Landmesser, U. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu482 · Cited by 9
Lipid Management in Diabetes with a Focus on Emerging Therapies
Hoe, E., & Hegele, R. A. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.012 · Cited by 9
Promising new therapies for the treatment of hypercholesterolemia
Valerio, M. G., Velayati, A., Jain, D., & Aronow, W. S. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1148136 · Cited by 9
Gupta, S. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s83719 · Cited by 9
Schludi, B., Giugliano, R. P., Sabatine, M. S., Raal, F. J., Teramoto, T., Koren, M. J., Stein, E. A., Wang, H., & Monsalvo, M. L. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.05.069 · Cited by 9
Self-citationContemporary and Novel Therapeutic Options for Hypertriglyceridemia
Bell, D. A., & Watts, G. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.001 · Cited by 9
Clinical Application of Genetic Testing in Heart Failure
Morales, A., & Hershberger, R. E. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0366-4 · Cited by 9
The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors
Nicholls, S. J. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1103-2 · Cited by 10
Cholesterol lowering with inclisiran: a new chapter in the PCSK9 story book
Santos, R. D., & Rocha, V. Z. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac656 · Cited by 9
Update of Clinical Trials of Anti-PCSK9 Antibodies
Wu, N., Li, S., & Li, J. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6582-9 · Cited by 8
PCSK9 Monoclonal Antibodies Have Come a Long Way
Zendjebil, S., & Steg, P. G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01243-1 · Cited by 8
Li, J., Wang, M., Qu, K., Sun, Y., Yin, Z., Dong, N., Sun, X., Xu, Y., Chen, L., Zhang, S., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.015 · Cited by 9
PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke
Zhou, L., Zhang, H., Wang, S., Zhao, H., Li, Y., Han, J., Zhang, H., Li, X., & Qu, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1327185 · Cited by 8
Evolution of LDL-C lowering medications and their cardiovascular benefits: Past, present, and future
Faluk, M. A., Wardhere, A., Mohamoud, A. A., Nor, M. A., Bampastsias, D., Oikonomou, E., Almubaid, Z., & Hemyari, B. A. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102637 · Cited by 8
Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database
Cicala, G., Rottura, M., Gianguzzo, V. M., Cristiano, F., Drago, S. F. A., Pallio, G., Irrera, N., Imbalzano, E., Spina, E., & Arcoraci, V. (2024) · Pharmaceuticals · doi:10.3390/ph17101365 · Cited by 8
Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention
Page, M. M., & Watts, G. F. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1035709 · Cited by 8
Potential of PCSK9 as a new target for the management of LDL cholesterol
Mombelli, G. G., Pavanello, C., & Castelnuovo, S. (2015) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s52961 · Cited by 8
Waite, L. H., Phan, Y. L., & Spinler, S. A. (2016) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2015.12.017 · Cited by 8
Antilipidemic Drug Therapy Today and in the Future
Kramer, W. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_15 · Cited by 8
Evolocumab for the treatment of hypercholesterolemia
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1365134 · Cited by 8
Genetic Aspects of Non-Alcoholic Fatty Liver Disease
Bogomolov, P., Kokina, K. Y., Mayorov, A. Y., & Mishina, E. Е. (2019) · Вопросы современной педиатрии · doi:10.15690/vsp.v17i6.1974 · Cited by 8
PCSK9 Inhibitors: From Nature’s Lessons to Clinical Utility
Raal, F. J., CHILTON, R. J., Ranjith, N., Rambiritch, V., Leisegang, R. F., Ebrahim, I. O., van Tonder, A., Shunmoogam, N., Bouharati, C., Musa, M. G., et al. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200213114138 · Cited by 8
Self-citationLu, H. S., & Daugherty, A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000166 · Cited by 8
Inia, J. A., van Nieuwkoop, A., Jukema, J. W., Rolin, B., Staarup, E. M., Mogensen, C., Princen, H. M. G., & van den Hoek, A. M. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100753 · Cited by 7
Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease
Hurwitz, M., Agboola, O. J., Gami, A., Williams, M. S., Virani, S. S., Sharma, G. V., & Patel, J. (2025) · US Cardiology Review · doi:10.15420/usc.2024.33 · Cited by 10
Vocca, C., Siniscalchi, A., Rania, V., Galati, C., Marcianò, G., Palleria, C., Catarisano, L., Gareri, I., Leuzzi, M., Muraca, L., et al. (2023) · Geriatrics · doi:10.3390/geriatrics8060122 · Cited by 7
Adverse Reactions to Evolocumab: Analysis of Real-World Data from EudraVigilance
Calapai, F., Mannucci, C., Currò, M., Cardia, L., Esposito, E., Calapai, G., & Ammendolia, I. (2024) · Pharmaceuticals · doi:10.3390/ph17030364 · Cited by 7
Zhang, A. M. C., Ziogos, E., Harb, T., Gerstenblith, G., & Leucker, T. M. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14272 · Cited by 7
Ye, D., Zhou, S. Y., Dai, X., Xu, H., Tang, Q., Huang, H., & Bi, F. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189161 · Cited by 8
Marquis‐Gravel, G., Bhatia, S., Brown, V., & Goodman, S. G. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.05.010 · Cited by 7
Limitations of cholesterol lowering with PCSK9 inhibitors
Thompson, G. R. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30060-8 · Cited by 7
A safety evaluation of evolocumab
Roth, E. M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1389892 · Cited by 7
Self-citationPCSK9 inhibitor valuation: A science‐based review of the two recent models
Baum, S. J., & Cannon, C. P. (2018) · Clinical Cardiology · doi:10.1002/clc.22924 · Cited by 7
Zhao, Z., Hu, X. Y., Zhang, Y., & Liu, D. (2020) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps31197 · Cited by 7
Use of apheresis in the age of new therapies for familial hypercholesterolaemia
Thompson, G. R. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000784 · Cited by 7
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review
McClintick, D. J., & Giugliano, R. P. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000897 · Cited by 7
Unraveling New Therapeutic Targets of Coronary Artery Disease by Genetic Approaches
Lee, S. E., & Kim, H.-S. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0985 · Cited by 7
Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy
Milionis, H. J., Liamis, G. L., & Elisaf, M. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.984682 · Cited by 7
The past, present and future of lipidlowering therapy
Najam, O., Lambert, G. C., & Ray, K. K. (2015) · Clinical Lipidology · doi:10.2217/clp.15.40 · Cited by 7
Designing an Orally Available Nontoxic p38 Inhibitor with a Fragment-Based Strategy
Guarnieri, F. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2486-8_15 · Cited by 7
Novel Therapies for Familial Hypercholesterolemia
Parizo, J. T., Sarraju, A., & Knowles, J. W. (2016) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-016-0486-2 · Cited by 7
Using human genetics to discover new therapeutic targets for plasma lipids
Cohen, J. C. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12521 · Cited by 7
Jensen, J. S., Weeke, P. E., Bang, L. E., Høfsten, D. E., Ripa, M. S., Schjerning, A.-M., Theilade, J., Køber, L., Gislason, G., & Pallisgaard, J. L. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022702 · Cited by 7
Elseweidy, M. M., El-Swefy, S. E., Younis, N. N., & Tarek, S. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04836-1 · Cited by 7
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Collins, P. D., & Sattar, N. A. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0795-9 · Cited by 7
Blom, D. J., Wasserman, S. M., & Stein, E. A. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1408237 · Cited by 7
Self-citationEchevarría, A. B., García-Díaz, J. D. D., Caixàs, A., Plana, N., Corral, M. Á. R., Bridges, I. M., Dhalwani, N. N., Menchen, S. G., & Ray, K. K. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.04.004 · Cited by 6
Nicholls, S. J., & Nelson, A. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2362644 · Cited by 6
Mao, R., Zhang, T., Yang, Z., & Li, J. (2024) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s492205 · Cited by 7
Monoclonal Antibodies for Lipid Management
Feinstein, M. J., & Lloyd‐Jones, D. M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0593-2 · Cited by 6
Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia
Khoury, É., Brisson, D., & Gaudet, D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1704728 · Cited by 6
McEvoy, J. W., Whelton, S. P., & Blumenthal, R. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00038-x · Cited by 6
Athyros, V. G., Τζιόμαλος, Κ., & Karagiannis, A. I. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1072047 · Cited by 6
Dyslipidaemia: what’s around the corner?
Wierzbicki, A. S., Perera, D., & Ewang-Emukowhate, M. (2014) · Clinical Medicine · doi:10.7861/clinmedicine.14-6-s41 · Cited by 6
Cheng, C., Sun, S.-J., Zhou, Y., & Yang, X. (2016) · Biomedical Reports · doi:10.3892/br.2016.766 · Cited by 6
Modern Management of Familial Hypercholesterolemia
Duell, P. B., & Jialal, I. (2016) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2016.29011.due · Cited by 6
Proprotein Convertase Subtilisin Kexin 9 Inhibitors
Pirillo, A., & Catapano, A. L. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.006 · Cited by 6
PCSK9 Inhibitors and Cardiovascular Disease: Impact on Cardiovascular Outcomes
Farmaki, P., Damaskos, C., Garmpis, N., Garmpi, A., Savvanis, S., & Diamantis, E. (2018) · Current Drug Discovery Technologies · doi:10.2174/1570163816666181211112358 · Cited by 6
Thonusin, C., Pantiya, P., Jaiwongkam, T., Kerdphoo, S., Arunsak, B., Amput, P., Palee, S., Pratchayasakul, W., Chattipakorn, N., & Chattipakorn, S. C. (2020) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001586 · Cited by 6
Liu, Y., & Han, B. (2021) · Transplant Immunology · doi:10.1016/j.trim.2021.101444 · Cited by 6
Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe
Schweitzer, M., Makhoul, S., Paliouras, M., Beitel, L. K., Gottlieb, B., Trifiro, M. A., Chowdhury, S. F., Zaman, N., Wang, E., Davis, H. R., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.032 · Cited by 6
Quiroga, B., Ramos, P. M., & Chiva, V. Á. (2020) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2020.11.004 · Cited by 6
Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors
Eisen, A., & Giugliano, R. P. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000332 · Cited by 6
Wang, W., Liu, C., & Cong, H. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416651721 · Cited by 6
Stummer, A., Ristl, R., Kogler, B., Muskovich, M., Kossmeier, M., & Stulnig, T. M. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02154-y · Cited by 5
Lian, P., Zhu, W.-Q., Zhao, W.-X., Huang, P., Ran, J., Tang, Y., Huang, X., & Li, R. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119982 · Cited by 5
Low-density lipoprotein cholesterol lowering therapies
Gadi, R., & Figueredo, V. M. (2014) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000193 · Cited by 5
Escobedo, R. R., Martínez, S. G., Naya, L. D., Gutiérrez, L. S., Fernández-Morera, J. L., Fernández, M. R., Faedo, C. M., González, F. V., & Torre, E. L. M. (2021) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2021.03.008 · Cited by 5
PCSK9 Inhibitors and Their Role in high-risk Patients in Reducing Ldl Cholesterol Levels: Evolocumab
Dahagam, C., Goud, A., Abdelqader, A., Hendrani, A. D., Feinstein, M. J., Qamar, A., Joshi, P. H., Swiger, K. J., Byrne, K., Quispe, R., et al. (2016) · Future Cardiology · doi:10.2217/fca.15.89 · Cited by 5
Shakir, A., Barron, K., & Modi, K. A. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101550 · Cited by 5
Ezetimibe and atherosclerotic cardiovascular disease: a systematic review and meta-analysis
Omidi, F., Rahmannia, M., Bonjar, A. H. S., Mohammadsharifi, P., Nasiri, M. J., & Sarmastzadeh, T. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1269172 · Cited by 5
Metadata
- Authors
- Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., Monsalvo, M. L., Tsirtsonis, K., Kim, J. B., Scott, R., Wasserman, S. M., & Stein, E. A.
- Affiliations
- University of Cape Town (ZA)
- National Institutes of Health (US)
- Midwest Institute for Clinical Research (US)
- Stellenbosch University (ZA)
- Sterling Research Group (US)
- Jacksonville Center for Clinical Research (US)
- Houston Methodist (US)
- Amgen (United States) (US)
- Amgen (United Kingdom) (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-08
- Volume
- 370
- Issue
- 19
- Pages
- 1809-1819
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2155259933
- Semantic Scholar
- 8d480541d9ba40d0cf45fea465f3b42bfc2b2f19
- Cited by
- 720
- References
- 16
- Citations by year
- 2026: 25 · 2025: 35 · 2024: 44 · 2023: 44 · 2022: 26 · 2021: 33 · 2020: 46 · 2019: 49 · 2018: 62 · 2017: 92 · 2016: 110 · 2015: 103 · 2014: 48
- FWCI
- 116.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Open University of Cape Town (University of Cape Town) (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evolocumab, PCSK9 inhibition, hyperlipidemia, LDL cholesterol lowering, monoclonal antibodies, atorvastatin, ezetimibe, apolipoprotein B, lipoprotein(a), triglycerides, non-HDL cholesterol, treatment safety
- MeSH terms
- Atorvastatin, Ezetimibe, Proprotein Convertase 9, Adult, Aged, Antibodies, Monoclonal, Azetidines, Combined Modality Therapy, Double-Blind Method, Female, Heptanoic Acids, Humans, Hyperlipidemias, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Serine Endopeptidases, Least-Squares Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Proprotein Convertases, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
